Literature DB >> 29474311

Identifying Poor-Performing Hospitals in the Medicare Hospital-Acquired Condition Reduction Program: An Assessment of Reliability.

Samuel Soltoff, Lane Koenig, Akinluwa A Demehin, Nancy E Foster, Christopher Vaz.   

Abstract

Centers for Medicare and Medicaid Services (CMS) estimated that Medicare's Hospital-Acquired Condition Reduction Program (HAC-RP) would reduce hospital payments by $364 million in fiscal year 2016. Although observers have questioned the validity of certain HAC-RP measures, less attention has been paid to the determination of low-performing hospitals (bottom quartile) and the reliability of penalty assignment. This study used publicly available data from CMS's Hospital Compare to simulate the consistency of hospitals' scores and the assignment of penalties under repeated measurement with no change in each hospital's underlying quality. The simulation showed that 64.0% of all hospitals and 40.6% of hospitals subject to payment penalty are statistically significantly different from the penalty threshold at the 95% confidence level. The proportion of hospitals statistically different from the threshold showed significant variation by ownership status, teaching status, bed size, and other factors. The simulation further showed that due only to chance, 18.0% of penalized hospitals would escape penalty on repeated measurement. Policymakers should consider alterations to the HAC-RP to improve its reliability.

Entities:  

Mesh:

Year:  2018        PMID: 29474311     DOI: 10.1097/JHQ.0000000000000128

Source DB:  PubMed          Journal:  J Healthc Qual        ISSN: 1062-2551            Impact factor:   1.095


  1 in total

1.  Medicare's Hospital Acquired Condition Reduction Program Disproportionately Affects Minority-serving Hospitals: Variation by Race, Socioeconomic Status, and Disproportionate Share Hospital Payment Receipt.

Authors:  Cheryl K Zogg; Jyothi R Thumma; Andrew M Ryan; Justin B Dimick
Journal:  Ann Surg       Date:  2020-06       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.